Director/PDMR Dealing

RNS Number : 5908B

Creo Medical Group PLC

04 April 2017

 

Creo Medical Group plc

Director/PDMR Dealing

The Company has been informed that directors Craig Gulliford (Chief Executive Officer) and Chris Hancock (Chief Technology Officer) have today each transferred ordinary shares of 0.1p each ("Ordinary Shares") in the Company from their personal holdings to their self-invested personal pensions ("SIPP"), as follows.

Director	Number of Ordinary Shares sold from personal account	Price per Ordinary Share sold	Number of Ordinary Shares purchased into SIPP	Price paid per Ordinary Share by SIPP
Craig Gulliford	92,750	82.5p	92,704	82.5p
Chris Hancock	106,084	82.5p	106,038	82.5p

Following these transactions, Mr Gulliford and Mr Hancock's total interest in the Company are 1,089,886 Ordinary Shares and 4,880,150 Ordinary Shares respectively.

Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Craig Gulliford
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.001 each GB00BZ1BLL44
b)	Nature of the transaction	Transfer of ordinary shares to self-invested personal pension (SIPP) via sale and purchase
c)	Price(s) and volume(s)	Price(s) Volume(s) Sale of shares from personal holding at 82.5p per share 92,750 Purchase by SIPP at 82.5p per share 92,704
d)	Aggregated information - Aggregated volume - Price	Weighted average price of 82.5p per share
e)	Date of the transaction	4 April 2017
f)	Place of the transaction	London Stock Exchange

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Chris Hancock
2	Reason for the notification
a)	Position/status	Chief Technology Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.001 each GB00BZ1BLL44
b)	Nature of the transaction	Transfer of ordinary shares to self-invested personal pension (SIPP) via sale and purchase
c)	Price(s) and volume(s)	Price(s) Volume(s) Sale of shares from personal holding at 82.5p per share 106,084 Purchase by SIPP at 82.5p per share 106,038
d)	Aggregated information - Aggregated volume - Price	Weighted average price of 82.5p per share
e)	Date of the transaction	4 April 2017
f)	Place of the transaction	London Stock Exchange

Contacts

Creo Medical:	Cenkos:	FTI Consulting:
Roseanne Varner [phone] [e-mail]	Ivonne Cantu / Camilla Hume (NOMAD) Michael Johnson / Russell Kerr (Sales) [phone]	Brett Pollard / Mo Noonan [phone] [e-mail]

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

 

END

 

 

DSHEAKLLELSXEFF